Navigation Links
ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
Date:4/8/2008

FREDERICK, Md., April 8, 2008 /PRNewswire/ -- ImQuest scientists Robert W. Buckheit, Jr., Ph.D. and Karen M. Watson, M.S. presented the results of studies performed with products licensed by ImQuest Life Sciences, Inc. at the recent Microbicides 2008, an international conference held in New Delhi, India and attended by microbicide scientists, developers, and care givers from around the world. Dr. Buckheit was invited to speak by the Conference organizers, presenting the results of ImQuest's current research on the pyrimidinedione series of microbicide candidates in a special symposium entitled "New Approaches to Microbicide Candidates". ImQuest is currently developing the highly unique, dual acting pyrimidinediones as potential microbicide candidates based on their significantly high potency against HIV-1, their unique mechanism of action, and their ability to potently suppress the sexual transmission of wild type and drug resistant viruses.

According to Dr. Buckheit (Executive Vice President and Chief Scientific Officer of ImQuest Life Sciences, Inc., and President of its subsidiary, ImQuest BioSciences, Inc.), "It was highly gratifying to speak on our novel pyrimidinedione products at this Conference and to have them recognized as a new approach to HIV prevention by the thousands of dedicated people leading these efforts around the world." ImQuest has obtained funding from the National Institutes of Health and The International Partnership for Microbicides to further develop these products.

At the conference, Ms. Watson (Manager, Topical Microbicide Research and Development) presented three papers, including additional data on the pyrimidinedione IQP-0528, newly emerging data on the microbicide candidate ISIS 5320 (IQP-0831), and results from laboratory studies performed using ImQuest's recently developed Microbicide Transmission and Sterilization Assay which quantifies the ability of microbicide products to completely suppress the sexual transmission of HIV.

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in the preclinical and clinical development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective and anti-cancer drug and vaccine development services to the biotechnology and pharmaceutical industry. Both companies are highly involved in efforts to develop an effective anti-HIV topical microbicide.

For further information regarding this press release please contact:

Robert W. Buckheit, Jr., Ph.D.

Executive Vice President and Chief Scientific Officer

ImQuest Life Sciences, Inc.

301-696-0274

rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest Life Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
2. Neuroscientists Offer Hope for Breast Cancer Patients Suffering From Chemobrain
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , Jan. 20, 2017 ResMed (NYSE: RMD ... ( Winter Haven, Florida ) today announced they have ... BMC and 3B will be permitted to sell their existing products ... a one-time settlement payment to 3B to close the ... not include an admission of liability or wrongdoing by any party. ...
(Date:1/21/2017)... Research and Markets has announced the addition ... Technology, Route Of Administration, End User - Forecast to 2025" ... ... at a CAGR of around 7.8% over the next decade to ... report analyzes the global markets for Advanced Drug Delivery across all ...
(Date:1/20/2017)... , Jan. 20, 2017  Ethicon Endo-Surgery, ... Megadyne Medical Products, Inc., a privately held ... markets electrosurgical tools used in operating rooms ... of Ethicon,s* advanced energy devices with Megadyne,s ... major step forward in Ethicon,s goal to ...
Breaking Medicine Technology:
(Date:1/23/2017)... NY (PRWEB) , ... January 23, 2017 , ... ... today that John J. Nelson, a senior accountant at the Firm, will participate in ... Make-A-Wish® Hudson Valley. Over 200 runners will race up 1,576 steps, a vertical distance ...
(Date:1/23/2017)... ... 23, 2017 , ... Wooden and plastic balance boards have been around since at least the ... Board is the first and only balance board to use a patent-pending design featuring ... at the same time as well as skill-level adjustable for all ages and abilities. ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... Crystallization in Process Chemistry by Applying Simple PAT Tools . , ... to isolate and purify the desired product. Chemists now spend more time ...
(Date:1/23/2017)... , ... January 23, 2017 ... ... Foundation (OREF), in partnership with the American Society of Anesthesiologists® (ASA®), the ... (APSF), the American Academy of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, ...
(Date:1/23/2017)... ... ... “Life Under Blankets”: an entrancing story about one woman's travels through the wilderness ... of published author, Kimberly Mitchell, who earned her bachelor’s degree in English education at ... master’s degree in education in the field of curriculum and instruction. Kimberly’s passion for ...
Breaking Medicine News(10 mins):